Owonikoko, T. K., K. P. Papadopoulos, M. L. Johnson, and E. al. “Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients With Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Final Efficacy and Safety Data”. SKIN The Journal of Cutaneous Medicine, vol. 2, Dec. 2018, p. S78, doi:10.25251/skin.2.supp.78.